CompletedPhase 2NCT00033462
Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer
Studying Adenocarcinoma of the gallbladder and extrahepatic biliary tract
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Philip Philip, DMDMayo Clinic
- Intervention
- erlotinib hydrochloride(drug)
- Enrollment
- 78 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2002
Study locations (1)
- Mayo Clinic, Rochester, Minnesota, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00033462 on ClinicalTrials.govOther trials for Adenocarcinoma of the gallbladder and extrahepatic biliary tract
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07265674A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract CancerJ-Pharma Co., Ltd.
- RECRUITINGPHASE3NCT06282575Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract CancerJazz Pharmaceuticals
- RECRUITINGNCT07007832Bile Omics for Diagnosing Indeterminate Biliary StricturesShanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- ACTIVE NOT RECRUITINGPHASE1NCT03257761Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder CancerUniversity of Southern California
See all trials for Adenocarcinoma of the gallbladder and extrahepatic biliary tract →